No Picture
News

ViaCyte’s Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies

SAN DIEGO: SAN DIEGO, Dec. 2, 2021 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announced publication of promising preliminary results of an ongoing, first-in-human Phase 1/2 study demonstrating that its stem cell-derived therapy can… Click here to view original post… […]

No Picture
News

Summit of Science

The tools of a scientist often feature items like microscopes and petri dishes. For an elite group of physiologists and biologists 40 years ago, they also included ice axes and belays.
[…]

No Picture
News

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical

SAN DIEGO: SAN DIEGO, Dec. 2, 2021 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co., Ltd. Jemincare will retain the relevant rights in the greater… Click here to view original post… […]

No Picture
News

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)—- $PHAS #NEJM–PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence Click here to view original post… […]

No Picture
News

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

SAN DIEGO: SAN DIEGO, Dec. 1, 2021 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-109 for the treatment of chondrosarcoma. "We… Click here to view original post… […]

No Picture
News

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

SAN DIEGO: SAN DIEGO, Dec. 1, 2021 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis® (carfilzomib) and dexamethasone (Kd) for the treatment of adult patients with relapsed… Click here to view original post… […]

No Picture
News

Quest Diagnostics Now Offers Biocept’s Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics

SECAUCUS, N.J. and SAN DIEGO: SECAUCUS, N.J. and SAN DIEGO, Dec. 1, 2021 /PRNewswire/ — Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services. Developed by Biocept, Inc…. Click here to view original post… […]

No Picture
News

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had… Click here to view original post… […]

No Picture
News

Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit

SAN DIEGO: SAN DIEGO, Dec. 1, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced a presentation at the first annual Rare & Genetic Kidney Disease Drug Development Summit. In the… Click here to view original post… […]

No Picture
News

Helixmith Announces 50% Enrollment in its Clinical Trial for COVID-19, involving TADIOS

SAN DIEGO: SAN DIEGO, Dec. 1, 2021 /PRNewswire/ — Helixmith Co., Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in… Click here to view original post… […]

No Picture
News

Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: Click here to view original post… […]

No Picture
News

Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may provide new hope for those in severe pain, today announced the completion of a positive safety review and enrollment of the… Click here to view original post… […]

No Picture
News

Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity

SAN DIEGO: SAN DIEGO, Nov. 30, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the closing of its previously announced private placement of equity. The Company received gross proceeds of… Click here to view original post… […]

No Picture
News

MEI Pharma Announces Proposed Public Offering of Common Stock

SAN DIEGO–(BUSINESS WIRE)–MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it plans to offer 17,500,000 shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day… Click here to view original post… […]

No Picture
News

Flu Virus Shells Could Improve Delivery of mRNA Into Cells

UC San Diego nanoengineers developed a new and potentially more effective way to deliver messenger RNA (mRNA) into cells. Their approach involves packing mRNA inside nanoparticles that mimic the flu virus—a naturally efficient vehicle for delivering genetic material such as RNA inside cells. Click here to view original post… […]

No Picture
News

BioCina officially opens full-service CDMO in Adelaide, Australia, including mRNA and pDNA cGMP manufacturing

SAN DIEGO and ADELAIDE, Australia: SAN DIEGO and ADELAIDE, Australia, Nov. 30, 2021 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines announces the official opening of its new biologics manufacturing facility in Adelaide, Australia…. Click here to view original post… […]

No Picture
News

Which side is which?: How the brain perceives borders

LA JOLLA—In the classic “Rubin’s vase” optical illusion, you can see either an elaborate, curvy vase or two faces, noses nearly touching. At any given moment, which scene you perceive depends on whether your brain is viewing the central vase shape to be the foreground or background of the picture…. Click here to view original post… […]

No Picture
News

New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing

CARLSBAD, Calif.: CARLSBAD, Calif., Nov. 30, 2021 /PRNewswire/ — For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target editing efficiency. Thermo Fisher Scientific introduced the… Click here to view original post… […]

No Picture
News

Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate

SAN DIEGO: SAN DIEGO, Nov. 30, 2021 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) today reported a successful Type C meeting with the U.S. Food and Drug Administration in which agreement was reached on the preliminary submission strategy for EVO100 for two investigational indications: the prevention of urogenital chlamydia in… Click here to view original post… […]

No Picture
News

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

SAN DIEGO: SAN DIEGO, Nov. 30, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical… Click here to view original post… […]

No Picture
News

ViaCyte Appoints Marty Lorenzo as General Counsel

SAN DIEGO: SAN DIEGO, Nov. 30, 2021 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the appointment of Marty Lorenzo as General Counsel. Mr. Lorenzo brings over 20 years in the legal profession leading corporate… Click here to view original post… […]

No Picture
News

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that restoration of retinal tissue was observed in a fourth patient enrolled in the Company’s Phase 1/2a clinical study of its lead product… Click here to view original post… […]

No Picture
News

After Big Pharma sparked interest in the US, Ablaze looks to bring radiopharmaceuticals overseas

Thanks in part to interest from Big Pharma players like Bayer and Novartis over the last decade, there’s been no shortage in cash for new companies looking to slay tumor cells with targeted radioisotopes. Now a transpacific upstart has hooked $75 million to bring the increasingly popular drugs to China…. Click here to view original post… […]

No Picture
News

ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

SAN DIEGO and SHANGHAI: SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ — ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the National Medical Products… Click here to view original post… […]